Annual report pursuant to Section 13 and 15(d)

Quarterly Results (Unaudited)

v3.7.0.1
Quarterly Results (Unaudited)
12 Months Ended
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Results (Unaudited)

16. Quarterly Results (Unaudited)

 

Selected quarterly financial data for 2016 and 2015 are contained in the Condensed Interim Financial Data table below.

 

($ in thousands except per share amounts)   4th Q     3rd Q     2nd Q     1st Q  
2016                        
Grant Revenues   $ -     $ -     $ -     $ -  
Research and development     93,876 (1)     2,093       2,368       3,342  
General and administrative     510       (199 )     1,836       1,992  
Total costs and expenses     94,386       1,894       4,204       5,334  
Operating loss     (94,386 )     (1,894 )     (4,204 )     (5,334 )
Other income (expense), net     (762 )     13       977       1,322  
Income tax benefit (provision)   $ 29,394     $ -     $ -     $ -  
Net (loss) income     (65,754 )     (1,881 )     (3,227 )     (4,012 )
Basic (loss) earnings per common share   $ (0.10 )   $ (0.00 )   $ (0.00 )   $ (0.01 )
(Loss) earnings per common share assuming dilution   $ (0.10 )   $ (0.00 )   $ (0.00 )   $ (0.01 )
                                 
2015                                
Grant Revenues   $ -     $ 24     $ 27     $ 27  
Research and development     41,578 (2)     2,177       1,946       1,560  
General and administrative     2,795       1,437       1,898       635  
Total costs and expenses     44,373       3,614       3,844       2,195  
Operating loss     (44,373 )     (3,590 )     (3,817 )     (2,168 )
Other income (expense), net     (1,376 )     3,082       1,246       (14,374 )
Income tax benefit (provision)     15,300       -       (52 )     -  
Net (loss) income   $ (30,449 )   $ (508 )   $ (2,623 )   $ (16,542 )
Basic (loss) earnings per common share   $ (0.05 )   $ (0.00 )   $ (0.00 )   $ (0.03 )
(Loss) earnings per common share assuming dilution   $ (0.05 )   $ (0.01 )   $ (0.01 )   $ (0.04 )

 

(1)   Includes impairment charge for the company’s IPR&D asset of $92,369,000
     
(2)   Includes impairment charge for the company’s IPR&D asset of $38,665,000